8.00
Xencor Inc stock is traded at $8.00, with a volume of 1.34M.
It is up +3.43% in the last 24 hours and down -24.39% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$7.735
Open:
$7.63
24h Volume:
1.34M
Relative Volume:
1.45
Market Cap:
$569.36M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.7682
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+5.68%
1M Performance:
-24.39%
6M Performance:
-68.75%
1Y Performance:
-66.51%
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XNCR
Xencor Inc
|
8.00 | 538.76M | 133.62M | -177.37M | 23.50M | -2.89 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-25 | Initiated | William Blair | Outperform |
Dec-12-24 | Initiated | Wells Fargo | Overweight |
Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Apr-16-24 | Reiterated | BTIG Research | Buy |
Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
May-19-23 | Initiated | BofA Securities | Buy |
Dec-06-22 | Initiated | Cowen | Outperform |
Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Jan-21-22 | Initiated | SMBC Nikko | Outperform |
Dec-15-21 | Initiated | H.C. Wainwright | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Mar-04-20 | Initiated | Barclays | Underweight |
Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
Nov-20-19 | Resumed | Guggenheim | Neutral |
Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jun-13-19 | Initiated | Mizuho | Buy |
Apr-12-19 | Initiated | Guggenheim | Buy |
Mar-27-19 | Initiated | Berenberg | Buy |
Mar-15-19 | Initiated | Raymond James | Outperform |
Sep-10-18 | Resumed | BTIG Research | Buy |
Mar-28-18 | Resumed | Leerink Partners | Outperform |
Mar-02-17 | Initiated | Instinet | Neutral |
Mar-02-17 | Reiterated | Wedbush | Outperform |
Oct-04-16 | Initiated | Piper Jaffray | Overweight |
Dec-22-15 | Initiated | Canaccord Genuity | Buy |
Aug-05-15 | Reiterated | MLV & Co | Buy |
Feb-12-15 | Reiterated | Oppenheimer | Outperform |
Jan-28-15 | Reiterated | MLV & Co | Buy |
Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor Inc (NASDAQ: XNCR) Jumps 2.45%: What Could Be On The Way Going Forward? - Stocksregister
Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Where are the Opportunities in (XNCR) - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases 3,171 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC - Defense World
Deutsche Bank AG Buys 20,128 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (XNCR) Stock Analysis: Exploring a Potential 266% Upside in Biotech Investments - DirectorsTalk Interviews
Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Life Sciences Companies Have New Avenue to Challenge Patent Applications After Federal Court Ruling - JD Supra
Xencor, Inc. (NASDAQ:XNCR) Position Boosted by Comerica Bank - Defense World
Xencor Inc. Reports Revenue Growth Amidst Ongoing R&D Investments - TipRanks
Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Investor Network: Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings - Defense World
Wedbush Comments on Xencor’s Q2 Earnings (NASDAQ:XNCR) - Defense World
Research Analysts Set Expectations for Xencor Q2 Earnings - Defense World
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating - Investing.com Nigeria
Q4 Earnings Forecast for Xencor Issued By William Blair - Defense World
What is Wedbush’s Estimate for Xencor Q4 Earnings? - Defense World
Barclays Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World
Xencor Inc earnings missed by $0.04, revenue topped estimates - Investing.com Nigeria
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Bar - GuruFocus
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Barclays | XNCR Stock News - GuruFocus
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating By Investing.com - Investing.com South Africa
Xencor Reports First Quarter 2025 Financial Results - BioSpace
Xencor: Q1 Earnings Snapshot - MySA
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
(XNCR) Technical Data - news.stocktradersdaily.com
Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush - Defense World
Healthy Upside Potential: Xencor Inc (XNCR) - Sete News
Xencor reports positive trial results for inflammatory bowel disease treatment - MSN
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Wells Fargo & Company MN Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Analyzing Xencor Inc (XNCR) After Recent Trading Activity - knoxdaily.com
Trading Day Triumph: Xencor Inc (XNCR) Ends at 10.58, a -0.19 Surge/Plunge - DWinneX
Is Xencor Inc (XNCR) a good investment opportunity? - uspostnews.com
Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Xencor Announces Promising Phase 1 Study Results - TipRanks
Raymond James Financial Inc. Invests $2.33 Million in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Stu - GuruFocus
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - BioSpace
Xencor posts trial data for bowel disease drug (XNCR:NASDAQ) - Seeking Alpha
Xencor advances ulcerative colitis treatment into Phase 2b study - Investing.com
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Study | XNCR Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):